Pfizer launches mRNA flu vaccine trial
Washington (AFP) - US pharmaceutical company Pfizer said Monday it had begun a clinical trial to test an influenza vaccine designed with the same mRNA technology behind its successful Covid-19 shot. The idea is to improve on the current generation of flu vaccines that have an efficacy of 40-60 percent against a disease that can cause up to 650,000 deaths a year. "The Covid-19 pandemic allowed us to deliver on the immense scientific opportunity of mRNA," Kathrin Jansen, head of vaccine research at Pfizer, said in a statement. "Influenza remains an area where we see a need for vaccines which cou......
Sep 28, 2021
